Myriad Genetics Stock - Analyst views and sector comparison on a quiet news day

Edited by ad hoc news Sector & Peer-Group Desk. Verified prior to publication on 06/19/2026, 20:30 CET. Details in the imprint.

Myriad Genetics (US62855J1043) has not issued fresh market-moving news in the past day, and no new top-tier analyst calls have crossed the tape. Against this backdrop, Friday’s view turns to the company’s position in the genetic testing sector and current expectations from Wall Street.

How Myriad compares with peers

Myriad Genetics specializes in molecular diagnostic tests, including hereditary cancer screening and pharmacogenomic panels, and competes with players such as Exact Sciences and Natera in various parts of the genetic testing market.

In recent quarters, Myriad has focused on stabilizing growth and improving profitability after a period of reimbursement pressure and portfolio reshaping, a trend that management emphasized in its latest earnings materials.

What analysts currently expect

Consensus data compiled by financial portals show that analysts remain divided on Myriad Genetics shares, with ratings typically clustered around Hold and a wide range of target prices that reflect differing views on execution risk and long-term demand for genetic testing.

Revenue expectations in those consensus snapshots point to low- to mid-single-digit percentage growth over the coming years, indicating a sector that is still expanding but at a more measured pace than during the early genomics boom.

The product behind the stock

Myriad Genetics generates most of its revenue from diagnostic tests for hereditary cancer risk, prenatal and reproductive health, and mental health pharmacogenomics, combining laboratory analysis with bioinformatics and clinical decision-support tools for physicians and patients.

Where the stock trades today

Myriad Genetics shares (US62855J1043) trade on the Nasdaq in US dollars; the latest available quote and market capitalization are published on major financial data platforms and the company’s investor-relations site as of 06/19/2026, 20:30 CET.

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.